Anti-PD-1 antibodies like cemiplimab and pembrolizumab are now approved for treating advanced nonmelanoma skin cancers, due to their high mutational burden, including cutaneous squamous cell carcinoma and basal cell carcinoma. This evidence concerns the gene PDCD1 and cutaneous squamous cell carcinoma.